Cited by

• Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL^PRO and 3CL^PRO proteases.

  Jade D, Ayyamperumal S, Tallapaneni V, Joghee Nanjan CM, Barge S, Mohan S, Nanjan MJ. Jade D, et al. Eur J Pharmacol. 2021 Jun 15;901:174082. doi: 10.1016/j.ejphar.2021.174082. Epub 2021 Apr 3. Eur J Pharmacol. 2021. PMID: 33823185 Free PMC article.
• AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter.

  Griffiths GO, FitzGerald R, Jaki T, Corkhill A, Reynolds H, Ewings S, Condie S, Tilt E, Johnson L, Radford M, Simpson C, Saunders G, Yeats S, Mozgunov P, Tansley-Hancock O, Martin K, Downs N, Eberhart I, Martin JWB, Goncalves C, Song A, Fletcher T, Byrne K, Lalloo DG, Owen A, Jacobs M, Walker L, Lyon R, Woods C, Gibney J, Chiong J, Chandiwana N, Jacob S, Lamorde M, Orrell C, Pirmohamed M, Khoo S; AGILE investigators. Griffiths GO, et al. Trials. 2021 Jul 26;22(1):487. doi: 10.1186/s13063-021-05458-4. Trials. 2021. PMID: 34311777 Free PMC article.
• Cyclosporin A as an Add-On Therapy to a Corticosteroid-Based Background Treatment in Patients with COVID-19: A Multicenter, Randomized Clinical Trial.

  Llanos Jiménez L, Alvarez-Alvarez B, Fonseca Aizpuru E, Peces-Barba G, Pindao Quesada G, Rodríguez Nieto MJ, Ruiz-Hornillos FJ, Seijo Maceiras L, Robles Barrena I, Mena-de-Cea A, Meijide-Míguez H, Sánchez-Pernaute O; CSACOVID-IISFJD Team. Llanos Jiménez L, et al. J Clin Med. 2024 Sep 4;13(17):5242. doi: 10.3390/jcm13175242. J Clin Med. 2024. PMID: 39274454 Free PMC article.
• The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design.

  Rejdak K, Fiedor P, Bonek R, Goch A, Gala-Błądzińska A, Chełstowski W, Łukasiak J, Kiciak S, Dąbrowski P, Dec M, Król ZJ, Papuć E, Zasybska A, Segiet A, Grieb P. Rejdak K, et al. Contemp Clin Trials. 2022 May;116:106755. doi: 10.1016/j.cct.2022.106755. Epub 2022 Apr 4. Contemp Clin Trials. 2022. PMID: 35390511 Free PMC article.
• A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19.

  Rossignol JF, Bardin MC, Fulgencio J, Mogelnicki D, Bréchot C. Rossignol JF, et al. EClinicalMedicine. 2022 Feb 28;45:101310. doi: 10.1016/j.eclinm.2022.101310. eCollection 2022 Mar. EClinicalMedicine. 2022. PMID: 35237748 Free PMC article.